Alto Neuroscience Inc(ANRO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ANRO Alto Neuroscience Inc

交易中 07-22 15:16:48 EDT

27.30

+0.23

+0.83%

最高27.59	最低26.00	成交量20.31万
今开26.45	昨收27.07	日振幅5.87%
总市值9.58亿	流通市值6.46亿	总股本3,509万
成交额552.15万	换手率0.86%	流通股本2,366万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience Inc","latestPrice":27.295,"timestamp":1784747803050,"preClose":27.07,"halted":0,"volume":203143,"delay":0,"changeRate":0.008311784263021848,"floatShares":23659400,"shares":35093900,"eps":-2.454556,"marketStatus":"交易中","change":0.225,"latestTime":"07-22 15:16:48 EDT","open":26.45,"high":27.59,"low":26.0001,"amount":5521520.592065999,"amplitude":0.058733,"askPrice":27.34,"askSize":241,"bidPrice":27.25,"bidSize":65,"shortable":3,"etf":0,"ttmEps":-2.454556,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784750400000},"marketStatusCode":2,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":27.07,"preHourTrading":{"tag":"盘前","latestPrice":27.39,"preClose":27.07,"latestTime":"08:44 EDT","volume":40,"amount":1092.8084,"timestamp":1784724284604,"change":0.32,"changeRate":0.011821,"amplitude":0.004167},"postHourTrading":{"tag":"盘后","latestPrice":27.07,"preClose":27.07,"latestTime":"19:34 EDT","volume":17112,"amount":463214.24,"timestamp":1784676849243,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.40755,"impliedVol":0.5511,"impliedVolPercentile":0.1355},"requestUrl":"/m/hq/s/ANRO/tweets","defaultTab":"tweets","newsList":[{"id":"2651117211","title":"Alto Neuroscience宣布1亿美元普通股注册直接发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117211","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651117211?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:40","pubTimestamp":1783946400,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Alto Neuroscience近日宣布，已确定其承销注册直接发行的定价。此次发行共计3，776，436股普通股，每股价格为26.48美元，预计总募资额约为1亿美元。　　Alto Neuroscience表示，此次募资所得款项，连同现有现金及现金等价物，将用于加速和扩展其核心候选药物ALTO-207的临床开发，包括计划开展一项针对难治性抑郁症的额外3期临床试验，其余部分将用于一般营运资金。近期股价信息显示，本次26.48美元的发行价接近其52周高点28.44美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-13/doc-inihsita5718384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161540568","title":"Alto Neuroscience公布1亿美元普通股承销注册直接发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1161540568","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161540568?lang=zh_cn&edition=full","pubTime":"2026-07-13 19:49","pubTimestamp":1783943352,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc (ANRO) 公布了其普通股承销注册直接发行的定价细节，此次发行规模达1亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129847437","title":"Alto Neuroscience计划新增III期临床试验 加速并扩展Alto-207临床开发进程 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1129847437","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129847437?lang=zh_cn&edition=full","pubTime":"2026-07-13 19:43","pubTimestamp":1783942998,"startTime":"0","endTime":"0","summary":"根据提交至美国证券交易委员会（SEC）的文件显示，Alto Neuroscience Inc（ANRO）正计划通过新增一项III期临床试验，以加速并扩展其候选药物Alto-207的临床开发项目。此举旨在进一步评估该药物在目标适应症中的疗效与安全性，标志着公司推进其核心管线的重要战略步骤。新的试验计划预计将丰富临床数据包，为后续的监管沟通与潜在商业化奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139073211","title":"Alto Neuroscience股东拟转售最多600万股普通股 已提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1139073211","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139073211?lang=zh_cn&edition=full","pubTime":"2026-04-11 04:03","pubTimestamp":1775851392,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Alto Neuroscience Inc的部分现有股东计划转售公司普通股，总规模最高达600万股。\n此次股票转售方案涉及二级市场交易，出售方为现有持股股东。文件未披露具体售股股东身份及售股时间表，但明确本次转售不会为公司带来任何融资收益。\n市场分析人士指出，此类股东减持行为通常需要关注其背后的动机，可能是投资组合调整、资金需求或对公司前景的判断。投资者应密切关注后续披露的售股细节及公司基本面变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133009356","title":"精神分裂症认知研究未达主要终点，Alto Neuroscience盘后重挫18.8%报19.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133009356","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133009356?lang=zh_cn&edition=full","pubTime":"2026-04-02 04:35","pubTimestamp":1775075712,"startTime":"0","endTime":"0","summary":"在备受瞩目的精神分裂症认知功能研究宣告未能达到主要临床终点后，生物制药公司Alto Neuroscience Inc（ANRO）股价在延长交易时段遭遇重挫，大幅下跌18.8%，最终报收于19.01美元。这一关键临床试验结果的失利，无疑给投资者对该公司核心管线前景的预期带来了显著冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167468244","title":"Alto Neuroscience成功研发Alto-101改良缓释日服口服制剂，计划寻求合作伙伴","url":"https://stock-news.laohu8.com/highlight/detail?id=1167468244","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167468244?lang=zh_cn&edition=full","pubTime":"2026-04-02 04:32","pubTimestamp":1775075578,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc宣布已成功开发出Alto-101的改良缓释型每日一次口服制剂。该突破性进展显著提升了用药便利性，公司表示将积极寻求该制剂版本的商业化合作机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164690093","title":"Alto Neuroscience Inc：概念验证研究中，Alto-101未达到主要终点的统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1164690093","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164690093?lang=zh_cn&edition=full","pubTime":"2026-04-02 04:31","pubTimestamp":1775075475,"startTime":"0","endTime":"0","summary":"在一项概念验证研究中，Alto Neuroscience Inc (ANRO) 宣布，其候选药物Alto-101未能达到研究预设的主要终点的统计学显著性。这一结果意味着，在该研究的主要评估指标上，Alto-101与对照组相比，未显示出具有统计学意义的差异。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172191634","title":"Alto Neuroscience Inc：Alto-207研发仍为公司首要任务；二期B阶段试验计划于2026年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1172191634","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172191634?lang=zh_cn&edition=full","pubTime":"2026-04-02 04:31","pubTimestamp":1775075471,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc 宣布，其核心候选药物Alto-207的研发工作依然是公司的重中之重。目前，该药物的二期B阶段临床试验正按计划推进，预计将于2026年上半年正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114948377","title":"Alto Neuroscience拟将募资用于支持难治性抑郁症药物Alto-207的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1114948377","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114948377?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:05","pubTimestamp":1773659132,"startTime":"0","endTime":"0","summary":"生物制药企业Alto Neuroscience宣布，计划将近期融资所得款项专项投入其核心管线药物Alto-207的临床开发。该药物主要针对现有疗法效果不佳的难治性抑郁症患者群体，目前正处于关键研究阶段。公司表示，此项资金部署将加速推进Alto-207的临床试验进程，有望为全球数百万耐药性抑郁症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156597496","title":"Alto Neuroscience宣布完成Alto-101治疗精神分裂症相关认知障碍二期概念验证研究患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1156597496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156597496?lang=zh_cn&edition=full","pubTime":"2026-02-13 21:05","pubTimestamp":1770987953,"startTime":"0","endTime":"0","summary":"Alto Neuroscience（股票代码：ANRO）已顺利完成其候选药物Alto-101针对精神分裂症相关认知障碍的第二期概念验证研究的患者招募工作。这项研究的完成标志着该药物临床开发进程中的一个重要里程碑，为后续评估其疗效与安全性奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605297811","title":"Alto Neuroscience, Inc.盘中异动 早盘快速下跌5.07%报16.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605297811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605297811?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:35","pubTimestamp":1768919724,"startTime":"0","endTime":"0","summary":"北京时间2026年01月20日22时35分，Alto Neuroscience, Inc.股票出现波动，股价大幅跳水5.07%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体跌幅为1.46%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120223524a73109b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120223524a73109b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518273478","title":"Alto Neuroscience, Inc.盘中异动 早盘股价大跌5.04%报3.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518273478?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:38","pubTimestamp":1741617481,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时38分，Alto Neuroscience, Inc.股票出现波动，股价大幅下挫5.04%。截至发稿，该股报3.37美元/股，成交量5.0522万股，换手率0.19%，振幅4.79%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223801a26a3e49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223801a26a3e49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517166178","title":"Alto Neuroscience, Inc.盘中异动 早盘股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517166178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517166178?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:45","pubTimestamp":1741272319,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时45分，Alto Neuroscience, Inc.股票出现异动，股价大幅下挫5.30%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体跌幅为0.47%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224519989eb7ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224519989eb7ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517741910","title":"Alto Neuroscience, Inc.盘中异动 早盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517741910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517741910?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:34","pubTimestamp":1741185292,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时34分，Alto Neuroscience, Inc.股票出现异动，股价大幅上涨5.14%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223453963add40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223453963add40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516084766","title":"Alto Neuroscience, Inc.盘中异动 早盘股价大涨5.72%报3.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516084766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516084766?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:22","pubTimestamp":1741101762,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时22分，Alto Neuroscience, Inc.股票出现异动，股价快速拉升5.72%。截至发稿，该股报3.32美元/股，成交量15.8829万股，换手率0.59%，振幅5.39%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232242abe7feef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232242abe7feef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516644634","title":"Alto Neuroscience, Inc.盘中异动 股价大涨24.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516644634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516644634?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012329,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Alto Neuroscience, Inc.股票出现异动，股价大幅上涨24.64%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223209abe6335f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223209abe6335f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514337007","title":"Alto Neuroscience, Inc.盘中异动 临近收盘急速下挫5.10%报2.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514337007","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514337007?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:54","pubTimestamp":1740689669,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时54分，Alto Neuroscience, Inc.股票出现波动，股价急速下跌5.10%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228045430a256cfe2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228045430a256cfe2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514019272","title":"Alto Neuroscience, Inc.盘中异动 股价大跌5.14%报2.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514019272","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514019272?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:17","pubTimestamp":1740500260,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时17分，Alto Neuroscience, Inc.股票出现波动，股价大幅跳水5.14%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600174098926361&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600174098926361&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512993271","title":"Alto Neuroscience, Inc.盘中异动 下午盘股价大跌5.06%报3.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512993271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512993271?lang=zh_cn&edition=full","pubTime":"2025-02-19 03:28","pubTimestamp":1739906909,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日03时28分，Alto Neuroscience, Inc.股票出现波动，股价快速下挫5.06%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体涨幅为1.03%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190328299627c706&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190328299627c706&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510733578","title":"Alto Neuroscience, Inc.盘中异动 股价大跌5.60%报3.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510733578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510733578?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:44","pubTimestamp":1739288664,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时44分，Alto Neuroscience, Inc.股票出现波动，股价急速下挫5.60%。Alto Neuroscience, Inc.股票所在的生物技术行业中，整体跌幅为1.83%。Alto Neuroscience, Inc.公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211234424a2420b76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211234424a2420b76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANRO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.altoneuroscience.com","stockEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":0.1904},{"period":"3month","weight":-0.0033},{"period":"6month","weight":0.5757},{"period":"1year","weight":8.9158},{"period":"ytd","weight":0.5208}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alto Neuroscience, Inc.于2019年3月25日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于通过利用其精准精神病学平台识别大脑生物标志物，开发针对精神疾病的个性化治疗方案。其研发管线包括针对重度抑郁症、双相抑郁、精神分裂症和帕金森病的临床阶段资产。","exchange":"NYSE","name":"Alto Neuroscience Inc","nameEN":"Alto Neuroscience Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alto Neuroscience Inc(ANRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alto Neuroscience Inc(ANRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alto Neuroscience Inc,ANRO,Alto Neuroscience Inc股票,Alto Neuroscience Inc股票老虎,Alto Neuroscience Inc股票老虎国际,Alto Neuroscience Inc行情,Alto Neuroscience Inc股票行情,Alto Neuroscience Inc股价,Alto Neuroscience Inc股市,Alto Neuroscience Inc股票价格,Alto Neuroscience Inc股票交易,Alto Neuroscience Inc股票购买,Alto Neuroscience Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alto Neuroscience Inc(ANRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alto Neuroscience Inc(ANRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}